Study of pembrolizumab for different cancers in Japan
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This trial tests a drug called pembrolizumab (Keytruda) to see if it helps people with several types of cancer, including relapsed or refractory lymphoma, melanoma, MSI-high or TMB-high solid tumors, and Merkel cell carcinoma. The goal is to understand if this immunotherapy can shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have one of the cancer types listed: classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, melanoma (completely removed, advanced, or metastatic), MSI-high or TMB-high solid tumor, or Merkel cell carcinoma.
- For most cancer types, your tumor must be measurable on a scan.
- You must be expected to live longer than 3 months (or 6 months for some groups).
- You should not have active cancer that spread to the brain or other parts that is growing or needs treatment.
- You must not have an active autoimmune disease that required treatment in the last 2 years.
- You must not have a serious infection, HIV, hepatitis B or C, or have had an organ or stem cell transplant recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial studies pembrolizumab, an immunotherapy medicine, in people with thymoma or thymic cancer that cannot be removed with surgery. It aims to see how well the treatment works and how safe it is, including whether your immune system can help control the cancer.
This trial tests whether injecting immune-boosting drugs directly into melanoma tumors, alongside the immunotherapy pembrolizumab, can help people whose cancer has not responded to previous immunotherapy. It aims to shrink tumors and improve treatment outcomes.
This early-stage trial tests ATG 037 to see if it’s safe and how it works in the body, as well as whether it may help people with advanced melanoma. It compares treatment given alone and treatment given together with pembrolizumab, especially in melanoma that has progressed after prior immunotherapy.
This study is testing whether the immunotherapy drug pembrolizumab (Keytruda) works better for people with advanced non-small cell lung cancer by looking at their immune system's T-cells (a type of white blood cell). The goal is to understand which patients benefit most, which could help guide more personalized treatment.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.